ENTRADA THERAPEUTICS, INC. Debt Securities, Available-for-sale, Unrealized Loss Position
ENTRADA THERAPEUTICS, INC. (TRDA) had Debt Securities, Available-for-sale, Unrealized Loss Position of $33.70 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Debt and Equity Securities
us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition · last filed 2026-08-05
- 2026-06-30: Debt Securities, Available-for-sale, Unrealized Loss Position $33.70M.
- 2026-03-31: Debt Securities, Available-for-sale, Unrealized Loss Position $54.40M.
- 2025-09-30: Debt Securities, Available-for-sale, Unrealized Loss Position $36.80M.
- 2025-06-30: Debt Securities, Available-for-sale, Unrealized Loss Position $82.00M.
| Period end | Debt Securities, Available-for-sale, Unrealized Loss Position |
|---|---|
| 2026-06-30 | $33.70M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $54.40M 10-Q · filed 2026-05-07 |
| 2025-09-30 | $36.80M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $82.00M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $67.20M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $99.30M 10-K · filed 2026-02-26 |
| 2024-09-30 | $8.80M 10-Q · filed 2024-11-05 |
| 2024-06-30 | $252.30M 10-Q · filed 2024-08-13 |
| 2024-03-31 | $244.20M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $101.70M 10-K · filed 2025-02-27 |
| 2023-09-30 | $248.60M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $272.10M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $95.20M 10-Q · filed 2023-05-10 |
| 2022-12-31 | $143.60M 10-K · filed 2024-03-13 |
| 2022-09-30 | $162.30M 10-Q · filed 2022-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |